Gilbert & Cook Inc. boosted its position in shares of Pfizer, Inc. (NYSE:PFE) by 11.7% during the first quarter, Holdings Channel reports. The fund owned 7,082 shares of the biopharmaceutical company’s stock after buying an additional 744 shares during the period. Gilbert & Cook Inc.’s holdings in Pfizer were worth $242,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently made changes to their positions in PFE. D Orazio & Associates Inc. raised its position in shares of Pfizer by 0.5% in the fourth quarter. D Orazio & Associates Inc. now owns 5,223 shares of the biopharmaceutical company’s stock worth $170,000 after buying an additional 28 shares during the last quarter. Stone House Investment Management LLC raised its position in shares of Pfizer by 0.9% in the first quarter. Stone House Investment Management LLC now owns 7,164 shares of the biopharmaceutical company’s stock worth $245,000 after buying an additional 66 shares during the last quarter. Naples Global Advisors LLC raised its position in shares of Pfizer by 0.3% in the first quarter. Naples Global Advisors LLC now owns 24,552 shares of the biopharmaceutical company’s stock worth $840,000 after buying an additional 79 shares during the last quarter. Pure Financial Advisors Inc. raised its position in shares of Pfizer by 0.4% in the first quarter. Pure Financial Advisors Inc. now owns 22,091 shares of the biopharmaceutical company’s stock worth $756,000 after buying an additional 84 shares during the last quarter. Finally, Alpha Windward LLC raised its position in shares of Pfizer by 1.1% in the first quarter. Alpha Windward LLC now owns 8,387 shares of the biopharmaceutical company’s stock worth $287,000 after buying an additional 89 shares during the last quarter. 69.94% of the stock is owned by institutional investors.

Pfizer, Inc. (PFE) traded up 0.165% on Wednesday, reaching $33.435. The company’s stock had a trading volume of 2,960,435 shares. The company has a 50 day moving average of $33.36 and a 200 day moving average of $33.37. Pfizer, Inc. has a 52 week low of $29.83 and a 52 week high of $35.38. The firm has a market capitalization of $199.53 billion, a price-to-earnings ratio of 24.459 and a beta of 1.00.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.02. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The firm had revenue of $12.90 billion for the quarter, compared to analysts’ expectations of $13.08 billion. During the same period in the prior year, the firm posted $0.64 earnings per share. The firm’s quarterly revenue was down 1.9% on a year-over-year basis. On average, analysts forecast that Pfizer, Inc. will post $2.56 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 1st. Investors of record on Friday, August 4th will be issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 3.83%. The ex-dividend date is Wednesday, August 2nd. Pfizer’s dividend payout ratio is presently 94.12%.

WARNING: “Gilbert & Cook Inc. Increases Position in Pfizer, Inc. (PFE)” was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://www.watchlistnews.com/gilbert-cook-inc-increases-position-in-pfizer-inc-pfe/1495661.html.

A number of brokerages recently commented on PFE. Jefferies Group LLC set a $35.00 price target on Pfizer and gave the company a “neutral” rating in a research note on Wednesday, August 2nd. Morgan Stanley reissued a “neutral” rating and set a $35.00 price target (down from $38.00) on shares of Pfizer in a research note on Monday, June 12th. Berenberg Bank set a $39.00 price target on Pfizer and gave the company a “neutral” rating in a research note on Tuesday, August 1st. Citigroup Inc. lowered Pfizer from a “neutral” rating to a “sell” rating and dropped their price target for the company from $38.00 to $31.00 in a research note on Tuesday, May 16th. Finally, BMO Capital Markets reaffirmed a “hold” rating and issued a $33.00 price objective on shares of Pfizer in a research note on Thursday, April 27th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $37.61.

In other Pfizer news, insider Alexander R. Mackenzie sold 15,000 shares of the company’s stock in a transaction on Monday, August 7th. The stock was sold at an average price of $33.50, for a total transaction of $502,500.00. Following the transaction, the insider now directly owns 151,474 shares in the company, valued at $5,074,379. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Ian C. Read sold 96,950 shares of the company’s stock in a transaction on Friday, August 4th. The stock was sold at an average price of $34.00, for a total value of $3,296,300.00. The disclosure for this sale can be found here. Corporate insiders own 0.06% of the company’s stock.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.